QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 soligenix-q2-2024-gaap-eps-131-beats-177-estimate

Soligenix (NASDAQ:SNGX) reported quarterly losses of $(1.31) per share which beat the analyst consensus estimate of $(1.77) by ...

 soligenix-plans-to-initiate-patient-enrollment-in-the-confirmatory-flash-2-study-with-hybryte-by-the-end-of-2024-continues-to-explore-the-potential-of-hybryte-in-treating-other-dermatological-conditions-such-as-psoriasis

PCG Digital -- Soligenix, Inc. (NASDAQ:SNGX), a late-stage biopharmaceutical company, is making significant strides in the trea...

 nano-cap-soligenix-stock-surges-over-200-on-tuesday-heres-why

Soligenix shares surged on heavy volume, following an interim update on the extended Hybryte treatment study.

 soligenix-shares-resume-trade
Soligenix Shares Resume Trade
07/09/2024 13:57:06

Core News & Articles
Market-Moving News for July 9th
07/09/2024 12:29:07

SNGX: 142% | Soligenix shares are trading higher after the company announced interim results for extended HyBryte treatment in ...

 soligenix-announces-hybryte-treatment-results-in-early-stage-cutaneous-t-cell-lymphoma

"In the Phase 3 FLASH study, HyBryte™ was shown to be efficacious with a promising safety profile. With limited treatment o...

 soligenix-announces-interim-results-for-extended-hybryte-treatment-in-early-stage-ctcl-patients

Soligenix, Inc. (NASDAQ:SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and comm...

 watching-soligenix-zacks-small-cap-research-gives-stock-32-price-valuation-says-model-is-highly-dependent-upon-continued-clinical-success-of-the-companys-pipeline-and-will-be-adjusted-accordingly-based-upon-future-clinical-results

https://s27.q4cdn.com/906368049/files/News/2024/Zacks_SCR_Research_06142024_SNGX_Bautz.pdf

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION